SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRX Global Inc. (SRXH) agreed to acquire all outstanding capital stock of CERo Therapeutics, Inc., the wholly owned operating subsidiary of CERo Therapeutics Holdings, Inc. At closing, SRX will issue Holdings shares calculated by dividing $1,000,000 by the lower of SRX’s closing price on NYSE American on the preceding trading day and its 20-day volume-weighted average price ending that day, forgive the Consolidated Note and related obligations, and assume approximately $1,562,000 of specified liabilities.
The Consolidated Note had outstanding principal of $8,249,643.77 as of October 6, 2026, plus accrued and unpaid interest, fees and expenses; its original principal amount was up to $11,666,108.77. Its maturity extends to five business days after the earlier of closing or valid termination. Closing depends on preferred-stock arrangements, consents and other conditions; SRX’s obligations are not subject to a financing condition.
Holdings may solicit alternatives during a 30-day go-shop period; a qualifying Superior Proposal received before that period ends may allow up to 45 additional days for negotiations. Either party may owe a $750,000 termination fee in specified circumstances, and SRX may also reimburse up to $100,000 of expenses in certain Company-breach terminations. Closing is contemplated for the first business day after the go-shop ends when conditions are met, and completion is not assured.
SRX Global Inc. committed $1.5 million to launch a new family of actively managed ETFs through its EMJX platform. Kupa AI, co-founded by Andy Kim, will oversee launch logistics; Eric Jackson, President of the EMJX Platform and Head of Asset Management, will manage the ETF family.
The first ETF is expected to be available to retail and institutional investors in the first quarter of 2027. It is designed to use an actively managed digital-asset hedging strategy powered by EMJX’s proprietary AI-driven regime model. SRX intends to dividend its ETF-launch holdings directly to shareholders; additional details, including timing and record date, will be announced later.
SRX Global Inc. (SRXH) reported that on September 8, 2026 it entered into a Limited Consent and Amendment Agreement with the Required Holders of its recently issued Series C convertible preferred stock. The consent relates to an existing stock repurchase plan for the company’s common stock.
Under this consent, the Required Holders agreed to consent to and waive certain rights so the company may maintain a stock repurchase plan allowing repurchases of up to the lesser of 10,000,000 shares of common stock or 50% of the issued and outstanding common stock at any given time, for an aggregate purchase price not to exceed $20,000,000, during the period ending July 7, 2027. The agreement follows the previously disclosed August 27, 2026 Securities Purchase Agreement under which accredited investors purchased 3,579 shares of Series C convertible preferred stock for $2.825 million.
SRX Global Inc. (SRXH) entered into a secured financing transaction with CERo Therapeutics Holdings, Inc. through a Consolidated Senior Secured Promissory Note$5,666,108.77 of CERo’s prior convertible grid notes and permits additional advances of up to $6,000,000, for a maximum aggregate loan of $11,666,108.77. On August 27, 2026, SRX Global funded an initial advance of $775,665.00.
The Note bears interest at 10% per annum, increasing during an Event of Default to up to 24.99% per annum, and currently matures on October 15, 2026, with SRX Global able to extend for up to four 30‑day periods. The debt is secured by a first‑priority pledge of all capital stock of CERo’s wholly owned subsidiary and a security interest in substantially all of the subsidiary’s assets, including intellectual property and assets related to CER-1236, and is guaranteed by the subsidiary.
SRX Global Inc. (SRXH) entered into a Securities Purchase Agreement with accredited investors for a private placement of its Series C Convertible Preferred Stock. The company issued 3,579 Series C shares for a purchase price of $2,862,500, paid by assigning Convertible Grid Promissory Notes of CERO Therapeutics Holdings, Inc. with an aggregate original principal of $2,812,500.
SRX Global has designated 4,000 Series C shares, each with a $1,000 stated value, ranking senior to common stock and pari passu with existing Series A and B preferred. The shares are convertible into common stock at a fixed Conversion Price of $2.1888 per share, with alternative conversion prices tied to 95% or 90% of the lowest five-day volume-weighted average price after stockholder approval and upon certain Triggering Events. The company may redeem all Series C shares in cash at 125% of a defined conversion-based value and must reserve at least 200% of the common shares needed for conversion.
In connection with the transaction, SRX Global entered into a Registration Rights Agreement requiring it to register for resale the common stock issuable upon conversion of the Series C Preferred Stock and upon exercise of related warrants. The securities were issued in an unregistered private offering under Section 4(a)(2) and Rule 506 of Regulation D.
SRX Global Inc. (SRXH) reported fiscal third quarter 2026 results highlighted by stronger revenue growth, narrower losses and a highly liquid balance sheet. Net sales rose 27% year over year to $3.4 million, while operating loss improved 63% to $3.2 million and net loss from continuing operations improved 40% to $4.1 million. Adjusted EBITDA loss improved 35% year over year to $1.6 million.
As of June 30, 2026, SRX Global reported $65.2 million in current assets and $2.4 million in total liabilities, with no debt outstanding. Net asset value was approximately $62.9 million or $3.22 per common share, above preliminary estimates of $60.0 million and $3.07 per share; the company also held $36.7 million in cash, cash equivalents and restricted cash.
The company completed the acquisition of EMJX, an AI-enabled digital-asset treasury platform, and reported hypothetical model results showing a maximum drawdown of about 10.6% versus 28–58% for benchmark comparators since February 2026. SRX approved a 10 million share repurchase program and declared a $0.05 per-share one-time dividend (about $1.3 million), while continuing to post sizable losses, including a nine-month net loss from continuing operations of $19.1 million.
SRX Global Inc. (SRXH) reported higher net sales but continued losses for the three and nine months ended June 30, 2026, while transforming its business and balance sheet. Net sales from continuing operations rose to $3.4 million from $2.7 million a year earlier, and to $9.6 million for the nine-month period. Loss from continuing operations improved to $4.1 million from $6.9 million in the quarter, and to $19.1 million for nine months, but the company remains meaningfully unprofitable.
Cash and cash equivalents increased to $36.7 million (including restricted cash) from $1.3 million, and total assets reached $145.4 million, driven largely by an $80.0 million asset acquisition of EMJX, an AI-driven digital-asset treasury management platform, recorded as indefinite-lived intangible assets. Total liabilities were only $2.4 million, with prior convertible debt eliminated, resulting in stockholders’ equity of $143.0 million. The company now operates two segments: the legacy Halo pet products business and the new EMJX platform, and holds $2.1 million of Ethereum and other financial investments, introducing digital-asset and trading-related volatility. NYSE American halted trading on June 23, 2026 due to low share price, and a 1‑for‑60 reverse stock split became effective July 6, 2026. Management states it sees no material uncertainties about the company’s ability to continue as a going concern over the next 12 months.
SRX Global Inc. filed an amended report to correct a typographical error, clarifying that Carolina Martinez serves as Chief Financial Officer, not Chief Executive Officer.
The company describes a private placement under a Securities Purchase Agreement allowing purchase of up to 10,000 shares of Series B convertible preferred stock and accompanying warrants for up to $8.0 million. An initial March 16, 2026 closing involved 5,660 Series B shares and 22,237,666 warrants for approximately $4.528 million in cash proceeds. At an Additional Closing on July 27, 2026, investors purchased 4,340 Series B shares and 284,156 warrants, generating approximately $3.472 million in cash. Warrant numbers reflect a previously announced 60-for-1 reverse stock split effective July 2, 2026. These securities were issued without registration in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
SRX Global Inc. reported an additional private placement closing under a Securities Purchase Agreement originally dated March 16, 2026. The agreement permits the sale of up to 10,000 shares of Series B convertible preferred stock for an aggregate purchase price of up to $8.0 million, together with accompanying warrants.
At the initial March 16, 2026 closing, the company sold 5,660 Series B shares and 22,237,666 warrants for cash proceeds of approximately $4.528 million. On July 27, 2026, at an Additional Closing, it sold 4,340 Series B shares and 284,156 warrants for approximately $3.472 million in cash, with the warrant number reflecting a 60-for-1 reverse stock split effective July 2, 2026.
The securities were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. These securities are restricted and may not be offered or sold in the United States absent registration or an applicable exemption.
SRX Global Inc. entered into a Limited Waiver and Consent Agreement with the Required Holders under its existing Securities Purchase Agreement that allows the company to return capital to common stockholders while that financing remains in place. The original agreement permits accredited investors to purchase up to 10,000 shares of Series B convertible preferred stock for an aggregate purchase price of up to $8.0 million in one or more closings.
Under the Waiver, the Required Holders consent to SRX Global’s plan to declare and pay a one-time cash dividend of $0.05 per share on common stock outstanding, payable on August 3, 2026 to stockholders of record at the close of business on July 22, 2026. They also consent to a stock repurchase plan under which the company may repurchase up to the lesser of 10,000,000 shares of common stock or 50% of the issued and outstanding common stock at any given time, for an aggregate purchase price not to exceed $20,000,000, during the period ending July 7, 2027.